公开(公告)号：DE60138408D1

公开(公告)日：2009-05-28

申请号：DE60138408

申请日：2001-11-06

Applicant: ID LELYSTAD INST DIERHOUDERIJ

Inventor： SMITH HILDA ELIZABETH

IPC: C12N15/31 ,  A61K38/00 ,  A61K38/16 ,  C07K14/315 ,  C07K16/12 ,  C12N1/21

Abstract: The invention relates to the field of diagnosis of and vaccination against Streptococcal infections and to the detection of virulence markers of Streptococci. The invention provides a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of said Streptococcus wherein said genomic fragment comprises at least a functional part of a fragment identifiable by hybridisation in Streptococcus suis to a nucleic acid or fragment thereof as shown in figure 5.

公开(公告)号：AT428787T

公开(公告)日：2009-05-15

申请号：AT01993615

申请日：2001-11-06

Applicant: ID LELYSTAD INST DIERHOUDERIJ

Inventor： SMITH HILDA

IPC: C12N15/31 ,  A61K38/00 ,  A61K38/16 ,  C07K14/315 ,  C07K16/12 ,  C12N1/21

Abstract: The invention relates to the field of diagnosis of and vaccination against Streptococcal infections and to the detection of virulence markers of Streptococci. The invention provides a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of said Streptococcus wherein said genomic fragment comprises at least a functional part of a fragment identifiable by hybridisation in Streptococcus suis to a nucleic acid or fragment thereof as shown in figure 5.

公开(公告)号：NZ548500A

公开(公告)日：2009-02-28

申请号：NZ54850006

申请日：2006-07-13

Applicant: ID LELYSTAD INST DIERHOUDERIJ

Inventor： KOOPMANS SIETSE JAN ,  ZDZISLAW MROZ

IPC: A01K67/00

Abstract: Disclosed is a method for generating a type II diabetes mellitus and/or Syndrome X model in pigs, said method comprising partially destructing pancreatic beta-cells in pigs by administration of streptozotocin (STZ) or alloxan, or a functional equivalent or derivative thereof, by slow infusion lasting at least 10 minutes, and selecting from said pigs a pig that comprises a fasting plasma glucose level higher than 6 mmol/L or a pig that comprises an elevated fasting plasma level of a functional equivalent of glucose as compared to a fasting plasma level of said functional equivalent of a healthy pig. Also disclosed is the use of said pig produced by the above method.

公开(公告)号：SI1088077T1

公开(公告)日：2008-02-29

申请号：SI9930990

申请日：1999-06-17

Applicant: ZONDHEID B V ID LELYSTAD INST

Inventor： PEETERS BERNARDUS PETRUS HUBER ,  DE LEEUW OLAV SVEN ,  KOCH GUUS ,  GIELKENS ARNOUD LEONARD JOSEF

IPC: C12N15/00 ,  C12N15/09 ,  A61K39/17 ,  A61K48/00 ,  A61P31/12 ,  C07K14/125 ,  C12N7/00 ,  C12N7/01 ,  C12N15/45 ,  C12N15/86 ,  C12Q1/00 ,  C12Q1/70

公开(公告)号：DE69936585D1

公开(公告)日：2007-08-30

申请号：DE69936585

申请日：1999-06-17

Applicant: ID LELYSTAD INST DIERHOUDERIJ

Inventor： PEETERS BERNARDUS PETRUS ,  DE LEEUW OLAV SVEN ,  KOCH GUUS ,  GIELKENS ARNOUD LEONARD

IPC: C12N15/09 ,  C12N15/45 ,  A61K39/17 ,  A61K48/00 ,  A61P31/12 ,  C07K14/125 ,  C12N7/00 ,  C12N7/01 ,  C12N15/86 ,  C12Q1/70

Abstract: The invention relates to the process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from said process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows the introduction of mutations, deletions, and/or insertions. The process can be used to modify the virulence of NDV, thereby generating new attenuated live vaccines with enhanced properties. The process can be used to modify the antigenic make-up of NDV, thus allowing the generation of live NDV marker vaccines which can be serologically distinguished from NDV field strains.

公开(公告)号：NZ534360A

公开(公告)日：2005-10-28

申请号：NZ53436003

申请日：2003-01-13

Applicant: ID LELYSTAD INSTIUUT VOOR DIER

Inventor： WILLEMSEN PETRUS THEODORUS JOH ,  WESTERVEEN SJOUKJE FETSJE ,  BAKKER DOUWE ,  VAN ZIJDERVELD FRED GOVERT ,  THOLE JELLE EGBERTUS RUDOLFUS

IPC: A61K39/00 ,  A61K39/005 ,  A61K39/02 ,  A61K39/04 ,  A61K39/085 ,  A61K39/09 ,  A61K39/108 ,  A61K39/135 ,  G01N33/53 ,  A61K39/145 ,  A61K39/155 ,  A61K39/215 ,  A61K39/245 ,  A61P31/04 ,  A61P31/06 ,  A61P31/12 ,  C07K14/35 ,  C07K16/12 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/31 ,  C12Q1/02 ,  C12Q1/04 ,  C12Q1/68 ,  G01N33/569

Abstract: A 9 kD Mycobacterium avium subspecies paratuberculosis protein or nucleic acid encoding such a protein. Also described is a vaccine for combating Mycobacterium avium subspecies paratuberculosis infection comprising said protein or nucleic acid.

公开(公告)号：BR0315934A

公开(公告)日：2005-09-13

申请号：BR0315934

申请日：2003-11-03

Applicant: ID LELYSTAD INST DIERHOUDERIJ

Inventor： RIJSEWIJK FRANCISCUS ANTONIUS

IPC: A61K39/205 ,  A61K39/245 ,  C07K14/03 ,  C07K14/145 ,  C12N15/82 ,  C07K14/005

公开(公告)号：MXPA02011415A

公开(公告)日：2004-02-26

申请号：MXPA02011415

申请日：2001-05-21

Applicant: ID LELYSTAD INST DIERHOUDERIJ

Inventor： VERHEIJE MONIQUE HELENE

IPC: C12N15/09 ,  A61K39/00 ,  A61K39/12 ,  A61P11/00 ,  A61P15/00 ,  A61P31/14 ,  C07K14/08 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N7/00 ,  C12N7/01 ,  C12N7/04 ,  C12N15/40 ,  C12N15/86

Abstract: La invencion se refiere al campo de Arterivirus y a vacunas dirigidas contra infecciones causadas por estos virus. La invencion proporciona una particula similar a Arterivirus que comprende al menos una primera proteina estructural derivada de un primer Arterivirus y una segunda proteina estructural, en donde la segunda proteina estructural al menos parcialmente no se deriva del primer Arterivirus.

公开(公告)号：HU0102429A3

公开(公告)日：2003-12-29

申请号：HU0102429

申请日：1999-06-17

Applicant: ID LELYSTAD INST DIERHOUDERIJ

IPC: C12N15/09 ,  A61K39/17 ,  A61K48/00 ,  A61P31/12 ,  C07K14/125 ,  C12N7/00 ,  C12N7/01 ,  C12N15/45 ,  C12N15/86 ,  C12Q1/70

Abstract: The invention relates to the process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from said process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows the introduction of mutations, deletions, and/or insertions. The process can be used to modify the virulence of NDV, thereby generating new attenuated live vaccines with enhanced properties. The process can be used to modify the antigenic make-up of NDV, thus allowing the generation of live NDV marker vaccines which can be serologically distinguished from NDV field strains.

公开(公告)号：CA2424400A1

公开(公告)日：2003-10-05

申请号：CA2424400

申请日：2003-04-03

Applicant: ID LELYSTAD INST DIERHOUDERIJ

Inventor： VAN RIJN PETRUS ANTONIUS ,  MEULENBERG JOHANNA JACOBA MARI

IPC: C12N15/09 ,  A61K39/12 ,  A61P31/12 ,  C07K14/08 ,  C12N7/00 ,  C12N7/01 ,  C12N7/04 ,  C12N7/08 ,  C12Q1/70 ,  C12N7/02 ,  C12N15/40 ,  G01N33/543

Abstract: The invention relates to the field of virology , more in particular to the field of vaccine production, more specifically to the in vitro propagation of virus, more specifically to the adaptation of virus to a cell line. The invention provides a method to determine the capability of an arterivirus to replicate in a green monkey cell line, comprising determining the amino acids at positions, which correspond to the amino acid positions 75-107 of GP2a of PRRSV isolate I-1102, more specifically amino acid position 88 and/or amino acid position 95 of said GP2a. The invention further discloses a method to produce arterivirus in green monkey cell line wherein the virulence of said arterivirus is maintained, with increased virus yield. The invention further provides a method to determine the attenuation of an arterivirus, comprising determining the amino acids at positions, which correspond to the amino acid positions 121-148 of GP5 of PRRSV isolate I- 1102, more specifically amino acid 136 of said GP5 and/or determining the amino acids at positions, which correspond to the amino acid positions 651-675 and/or amino acid positions 2331-2355 of ORF1ab of PRRSV isolate I-1102, more specifically amino acid 663 and/or 2343 of said ORF1ab. The invention also provides a method to attenuate the virulence of said arterivirus by changing said amino acids.